IE72181B1 - Bacterin for the treatment of Necrophorum diseases and a method for the production thereof - Google Patents

Bacterin for the treatment of Necrophorum diseases and a method for the production thereof

Info

Publication number: IE72181B1
Authority: IE; Ireland
Prior art keywords: necrophorum; bacterin; sheep; cattle; inactivated
Prior art date: 1990-06-07

Application number

IE194091A

Other languages

English (en)

Other versions

IE911940A1 (en

Inventor

John N Berg

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-06-07

Filing date

1991-06-06

Publication date

1997-03-26

1991-06-06 Application filed by Bayer Ag filed Critical Bayer Ag

1991-12-18 Publication of IE911940A1 publication Critical patent/IE911940A1/en

1997-03-26 Publication of IE72181B1 publication Critical patent/IE72181B1/en

Links

238000004519 manufacturing process Methods 0.000 title claims description 4
238000000034 method Methods 0.000 title abstract description 18
201000010099 disease Diseases 0.000 title description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 11
238000011282 treatment Methods 0.000 title description 7
241000605952 Fusobacterium necrophorum Species 0.000 claims abstract description 38
241000283690 Bos taurus Species 0.000 claims abstract description 37
241001494479 Pecora Species 0.000 claims abstract description 31
208000010801 foot rot Diseases 0.000 claims abstract description 27
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 12
239000002671 adjuvant Substances 0.000 claims description 9
241001465754 Metazoa Species 0.000 abstract description 3
206010019692 hepatic necrosis Diseases 0.000 abstract 1
231100000149 liver necrosis Toxicity 0.000 abstract 1
241000699670 Mus sp. Species 0.000 description 10
229960002433 cysteine Drugs 0.000 description 10
229940041514 candida albicans extract Drugs 0.000 description 9
239000012138 yeast extract Substances 0.000 description 9
230000001154 acute effect Effects 0.000 description 7
210000004556 brain Anatomy 0.000 description 7
238000001802 infusion Methods 0.000 description 7
238000002255 vaccination Methods 0.000 description 7
229960005486 vaccine Drugs 0.000 description 7
241000282849 Ruminantia Species 0.000 description 6
239000006161 blood agar Substances 0.000 description 6
230000003902 lesion Effects 0.000 description 6
230000017074 necrotic cell death Effects 0.000 description 6
241000605909 Fusobacterium Species 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
230000002779 inactivation Effects 0.000 description 5
229960000380 propiolactone Drugs 0.000 description 5
230000009467 reduction Effects 0.000 description 5
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
229930182566 Gentamicin Natural products 0.000 description 4
206010024652 Liver abscess Diseases 0.000 description 4
229940024546 aluminum hydroxide gel Drugs 0.000 description 4
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
239000007927 intramuscular injection Substances 0.000 description 4
238000010255 intramuscular injection Methods 0.000 description 4
238000011218 seed culture Methods 0.000 description 4
201000004624 Dermatitis Diseases 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000000427 antigen Substances 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
229960002518 gentamicin Drugs 0.000 description 3
244000144980 herd Species 0.000 description 3
230000036039 immunity Effects 0.000 description 3
239000007928 intraperitoneal injection Substances 0.000 description 3
239000000902 placebo Substances 0.000 description 3
229940068196 placebo Drugs 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
230000001018 virulence Effects 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
206010050473 Abscess limb Diseases 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
239000008272 agar Substances 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
229940024545 aluminum hydroxide Drugs 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
235000015278 beef Nutrition 0.000 description 2
244000309466 calf Species 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229960001305 cysteine hydrochloride Drugs 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000000415 inactivating effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
239000000203 mixture Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000007918 pathogenicity Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
229940033663 thimerosal Drugs 0.000 description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
241000606125 Bacteroides Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229930182504 Lasalocid Natural products 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
241000580463 Nicrophorus Species 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
238000013459 approach Methods 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
244000309464 bull Species 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
239000003224 coccidiostatic agent Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000013068 control sample Substances 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
244000309465 heifer Species 0.000 description 1
BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
229940025294 hemin Drugs 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
239000002555 ionophore Substances 0.000 description 1
230000000236 ionophoric effect Effects 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
238000002955 isolation Methods 0.000 description 1
BBMULGJBVDDDNI-OWKLGTHSSA-N lasalocid Chemical compound C([C@@H]1[C@@]2(CC)O[C@@H]([C@H](C2)C)[C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCC=2C(=C(O)C(C)=CC=2)C(O)=O)C[C@](O)(CC)[C@H](C)O1 BBMULGJBVDDDNI-OWKLGTHSSA-N 0.000 description 1
229960000320 lasalocid Drugs 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229940029985 mineral supplement Drugs 0.000 description 1
235000020786 mineral supplement Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000012856 packing Methods 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
239000011369 resultant mixture Substances 0.000 description 1
239000000523 sample Substances 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
239000011669 selenium Substances 0.000 description 1
238000003307 slaughter Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
238000012360 testing method Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
239000001974 tryptic soy broth Substances 0.000 description 1
108010050327 trypticase-soy broth Proteins 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
235000012711 vitamin K3 Nutrition 0.000 description 1
239000011652 vitamin K3 Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
229940041603 vitamin k 3 Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/114—Fusobacterium
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IE194091A 1990-06-07 1991-06-06 Bacterin for the treatment of Necrophorum diseases and a method for the production thereof IE72181B1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US53489490A	1990-06-07	1990-06-07

Publications (2)

Publication Number	Publication Date
IE911940A1 IE911940A1 (en)	1991-12-18
IE72181B1 true IE72181B1 (en)	1997-03-26

Family

ID=24131961

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IE194091A IE72181B1 (en)	1990-06-07	1991-06-06	Bacterin for the treatment of Necrophorum diseases and a method for the production thereof

Country Status (8)

Country	Link
US (1)	US6132709A (de)
EP (2)	EP0674905B1 (de)
AU (1)	AU644440B2 (de)
CA (1)	CA2043932C (de)
DE (2)	DE69116606T2 (de)
ES (2)	ES2186694T3 (de)
IE (1)	IE72181B1 (de)
NZ (1)	NZ238378A (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5455034A (en) *	1992-06-26	1995-10-03	Kansas State University Research Foundation	Fusobacterium necrophorum leukotoxoid vaccine
CA2138778C (en) *	1992-06-26	2003-03-11	Tiruvoor G. Nagaraja	Fusobacterium necrophorum leukotoxoid vaccine
US5861162A (en) *	1995-06-07	1999-01-19	Kansas State University Research Foundation	Multivalent inocula for lessening incidence of liver abscesses in cattle
ATE506074T1 (de) *	1995-06-07	2011-05-15	Univ Kansas State	Actinomyces pyogenes und actinomyces pyogenes/fusobakterium necrophorum impfstoffe zur immunisierung von vieh und schafen
US6632439B2 (en)	1999-09-29	2003-10-14	Novartis Animal Health, Inc.	Fusobacterium necrophorum vaccine and method for making such vaccine
US6548069B2 (en)	2001-02-03	2003-04-15	Hmv Associates, Inc.	Multivalent Mycoplasma bacterin
AU2009204952B2 (en) *	2008-01-18	2013-02-07	Werner Lubitz	Bacterial ghost (BG) production process using betapropiolactone (BLP) for final inactivation
CN102648003B (zh)	2009-10-09	2016-01-13	儿童医疗中心有限公司	选择性裂解的全细胞疫苗
BR122019025362B1 (pt) *	2012-11-29	2022-07-26	Cornell University	Uso de uma composição veterinária
WO2025160664A1 (en) *	2024-01-31	2025-08-07	University Of Saskatchewan	Methods and uses of fusobacterium necrophorum immunogenic compositions and vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA984293A (en) *	1971-08-20	1976-02-24	Richard W. Moore	Medium and method for growth of superiorly antigenic equine infectious anemia virus and production of immunizing vaccine therefrom
FR2174745A1 (en) *	1972-03-09	1973-10-19	Inst Elevage Med Vet	Mixed veterinary vaccine - active against symptomatic and bacterial anthrax
US4061751A (en) *	1976-07-22	1977-12-06	American Cyanamid Company	6-Substituted 3-nitroimidazo[1,2-b]pyridazine for the control of foot rot and liver lesions in ruminant animals
US4203968A (en) *	1978-08-18	1980-05-20	Iowa State University Research Foundation, Inc.	Combination vaccine for swine dysentery and method of use
DE3886332T2 (de) *	1987-09-28	1994-03-31	Beecham Inc	Inaktivierung von Viren und Bakterien.

1991
- 1991-05-25 DE DE69116606T patent/DE69116606T2/de not_active Expired - Fee Related
- 1991-05-25 EP EP95105058A patent/EP0674905B1/de not_active Expired - Lifetime
- 1991-05-25 ES ES95105058T patent/ES2186694T3/es not_active Expired - Lifetime
- 1991-05-25 DE DE69133172T patent/DE69133172T2/de not_active Expired - Fee Related
- 1991-05-25 ES ES91108517T patent/ES2084057T3/es not_active Expired - Lifetime
- 1991-05-25 EP EP91108517A patent/EP0460480B1/de not_active Expired - Lifetime
- 1991-06-04 NZ NZ238378A patent/NZ238378A/en not_active IP Right Cessation
- 1991-06-04 AU AU78177/91A patent/AU644440B2/en not_active Ceased
- 1991-06-05 CA CA002043932A patent/CA2043932C/en not_active Expired - Lifetime
- 1991-06-06 IE IE194091A patent/IE72181B1/en not_active IP Right Cessation
1992
- 1992-01-24 US US07/825,465 patent/US6132709A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69116606T2 (de)	1996-05-30
EP0460480A2 (de)	1991-12-11
EP0460480B1 (de)	1996-01-24
ES2186694T3 (es)	2003-05-16
EP0674905B1 (de)	2002-12-11
NZ238378A (en)	1992-12-23
AU644440B2 (en)	1993-12-09
DE69133172D1 (de)	2003-01-23
US6132709A (en)	2000-10-17
EP0674905A3 (de)	1995-12-06
CA2043932A1 (en)	1991-12-08
CA2043932C (en)	2006-09-12
DE69133172T2 (de)	2003-04-30
EP0460480A3 (en)	1992-04-01
DE69116606D1 (de)	1996-03-07
ES2084057T3 (es)	1996-05-01
AU7817791A (en)	1991-12-12
EP0674905A2 (de)	1995-10-04
IE911940A1 (en)	1991-12-18

Legal Events

Date	Code	Title	Description
2011-03-30	MM4A	Patent lapsed

Publication	Publication Date	Title
RU2194752C2 (ru)	2002-12-20	ШТАММ И КУЛЬТУРА ШТАММА Streptococcus equi TW 928 ДЛЯ ВАКЦИНАЦИИ ЛОШАДЕЙ
AU782508B2 (en)	2005-08-04	Vaccines for mycoplasma bovis and methods of use
SK15792003A3 (sk)	2005-09-08	Použitie Mycoplasma hyopneumoniae na výrobu liečiva
Pipano	1981	Schizonts and tick stages in immunization against Theileria annulata infection
JP5651677B2 (ja)	2015-01-14	各種血清型のブタ連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｓｕｉｓ）細菌から防御するためのワクチン
JP2004536106A (ja)	2004-12-02	マイコプラズマ・ボビスワクチンおよび動物の肺炎を減少させる方法
EP0460480B1 (de)	1996-01-24	Bacterin zur Behandlung von Necrophorum-Krankheiten und Verfahren zur Herstellung
US4888169A (en)	1989-12-19	Bordetella Bronchiseptica vaccine
AU2017375720B2 (en)	2024-11-14	Oral vaccine against ruminant respiratory disease comprising polyvinylpyrrolidone
JP3178720B2 (ja)	2001-06-25	パスツレラ・ムルトシダのトキソイドワクチン
WO2016119078A1 (zh)	2016-08-04	副猪嗜血杆菌lc株与lz-20100109株的联合应用
Donachie	1995	Vaccine development against Pasteurella haemolytica infections in sheep
US5019388A (en)	1991-05-28	Bordetella bronchiseptica vaccine
RU2112544C1 (ru)	1998-06-10	Вакцина против сибирской язвы и эмфизематозного карбункула живая ассоциированная и способ профилактики этих заболеваний
Garba et al.	1986	Immunogenicity of oil-based contagious bovine pleuropneumonia vaccine in cattle
Roshdy et al.	2023	Preparation of a newly developed trivalent Pasteurella multocida, Avibacterium paragallinarum, and Ornithobacterium rhinotracheale vaccine with an evaluation of its protective efficacy in chickens
IE84075B1 (en)	2005-11-30	Bacterin for the treatment of liver necrosis caused by F. Necrophorum
Navruzshoeva et al.	2022	Current trends in increasing the biological activity of vaccine strains of Bacillus anthracic
ur REHMAN	2023	HEMORRHAGIC SEPTICEMIA-MASTITIS VACCINE
CA1324075C (en)	1993-11-09	Bordetella bronchiseptica vaccine
CA1057658A (en)	1979-07-03	Vaccine for immunization of swine against bordetella bronchiseptica infection and method of use
Walker	1997	Bacterial vaccines
Mizutani et al.	1983	Round Table I: Immunization and Treatment
SHEEP	2013	Edinburgh EH17 7JH, Scotland
Irvin	1981	infected ticks, but during the early stage of these experiments it became evident that animals surviving an infection caused by ticks were more strongly protected against re-exposure to ticks than animals surviving a blood transmitted infection (Sergent et al